About 300 reports

  • BIOCON
  • Marketing Authorization Holder

The global biosimilars market projected to grow at a CAGR of 31.7% during the forecast period. The biosimilars market is expected to reach USD 23.63 billion by 2023 from USD 5.95 billion in 2018, at a CAGR of 31.7%. Factors driving the growth of this market include increasing demand for biosimilar drugs due to their cost-effectiveness,...

  • Monoclonal Antibody
  • Targeted Therapy
  • North America
  • United States
  • Market Size
  • Biocon Limited - Early Stage Pipeline Products
  • Biocon Limited - Pipeline by Indication, 2016

Biocon Limited - Product Pipeline Review - 2016 Summary Global Markets Direct’s, ‘Biocon Limited - Product Pipeline Review - 2016’, provides an overview of the Biocon Limited’s pharmaceutical research and development focus. The report provides comprehensive information on the therapeutics under development by Biocon...

  • Insulin
  • Targeted Therapy
  • World
  • Product Initiative
  • Biocon Limited

TABLE OF CONTENTS (##/ ##) ##.

  • Targeted Therapy
  • Therapy
  • World
  • Supply
  • Remicade group
  • The following compounds are being studied as potential biosimilars:
  • BIOSIMILARS: MABS & BIOLOGICS PIPELINE

The biosimilars are poised to capture an unprecedented position in the biopharmaceutical industry driven by an increased extent of adoption and growing investment and deal making activity globally. The global biosimilars market is predicted to cross US$ 25 Billion mark by 2020. With the continuous increasing demand for biologics,...

  • Targeted Therapy
  • World
  • Market Size
  • Amgen Inc.
  • Biocon Limited

The company has received approval for tbo-filgrastim (XM## filgrastim).

  • Targeted Therapy
  • Biocon Limited
  • Mylan Inc.
  • Pfizer Inc.
  • Sandoz Inc.

Filgrastim is very similar to a human protein called granulocyte-colony-stimulating factor (G-CSF).

  • Biosimilar
  • Targeted Therapy
  • United States
  • World
  • Sandoz Inc.
  • 5. ALL THE TRIALS INCLUDED ARE UNIQUE TRIALS.

## ## ## ## ## ## ## Sanofi ## ## ## ## ## ## ## Sarah Cannon Research Institute LLC ## ## ## ## ## ## ## Johnson & Johnson ## ## ## ## ## ## ## GlaxoSmithKline Plc ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ##

  • Clinical Trial
  • Drug Discovery And Development
  • Targeted Therapy
  • World
  • Product Initiative
  • Branded Name

The global immunotherapy drugs market is projected to reach USD 201.52 billion by 2021 from USD 108.41 billion in 2016, growing at a CAGR of 13.5% during the forecast period of 2016 to 2021. In this report, the immunotherapy drugs market is segmented on the basis of type of drugs, therapy area, end user, and region. Increasing adoption...

  • Monoclonal Antibody
  • Targeted Therapy
  • North America
  • United States
  • World
  • Clinical Trial profile. 59 Trial Title
  • CLINICAL TRIAL PROFILE SNAPSHOTS

One anti-drug antibody was observed for ALXN## and one for Soliris.

  • Blood Disease
  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • Alexion Pharmaceuticals, Inc.
  • Clinical Trial profile. 33 Trial Title
  • Clinical Trial profile. 159 Trial Title

Lymphoblastic Lymphoma Global Clinical Trials Review, H2, 2017 Summary GlobalData’s clinical trial report, “Lymphoblastic Lymphoma Global Clinical Trials Review, H2, 2017" provides an overview of Lymphoblastic Lymphoma clinical trials scenario. This report provides top line data relating to the clinical...

  • Cancer
  • Clinical Trial
  • Targeted Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 433 Trial Title
  • Clinical Trial profile. 1946 Trial Title

The prominent features of this report are - ##.

  • Leukemia
  • Monoclonal Antibody
  • Targeted Therapy
  • United States
  • World
  • CLINICAL TRIAL PROFILE SNAPSHOTS

The prominent features of this report are - ##.

  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative
  • Alexion Pharmaceuticals, Inc.

The prominent features of this report are - ##.

  • Clinical Trial
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative

Hoffmann-La Roche Ltd arGEN-X BV ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## ## Applied BioMath LLC ## ## ## ## ## Amgen Inc ## ## ## ## ## Almirall SA Source: GlobalData' s Pharma Intelligence C

  • Autoimmune Disease
  • Monoclonal Antibody
  • Targeted Therapy
  • World
  • Product Initiative

## ## ## ## Merck & Co Inc ## ## ## ## ## Groupe Francophone des Myelodysplasies ## ## ## ## ## Daiichi Sankyo Co Ltd ## ## ## ## ## CTI BioPharma Corp ## ## ## ## ## Celerion Inc ## ## ## ## ## Bristol-Myers Squibb C

  • Cancer
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Celgene Corporation

Monday, April ##, ##:##-##:## p. m.

  • Cancer
  • Clinical Trial
  • Targeted Therapy
  • World
  • Product Initiative
  • Clinical Trial profile. 1719 Trial Title
  • Clinical Trial profile. 2425 Trial Title

Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Multiple Myeloma (Kahler Disease) Global Clinical Trials Review, H1, 2018" provides an overview of Multiple Myeloma (Kahler Disease) clinical trials scenario.This report provides...

  • Clinical Trial
  • Oncology
  • Targeted Therapy
  • World
  • Celgene Corporation

In the supportive care space, several filgrastim (Amgen' s Neupogen) biosimilars are already marketed in the ##MM.

  • Targeted Therapy
  • AbbVie Inc.
  • Amgen Inc.
  • AstraZeneca PLC
  • Eli Lilly & Co.
  • 5. All the trials included are unique trials.

The prominent features of this report are - ##.

  • HIV AIDS
  • Targeted Therapy
  • United States
  • World
  • Product Initiative
  • Clinical Trial profile. 181 Trial Title
  • Clinical Trial profile. 125 Trial Title

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Progenics Pharmaceuticals Inc ## ## ## ## ## ## ## ## United Therapeutics Corp ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## APEIRON Biologics AG ## ## ## ## ## ## ## ## Pfizer Inc ## ## ## ## ## ## ## ## Y-mAbs Therapeutics Inc ##

  • Clinical Trial
  • Oncology
  • Targeted Therapy
  • World
  • Progenics Pharmaceuticals, Inc.

Hoffmann-La Roche Ltd ## ## ## ## ## ## ## ## Merck & Co Inc ## ## ## ## ## ## ## ## Bristol-Myers Squibb Company ## ## ## ## ## ## ## ## Novartis AG ## ## ## ## ## ## ## ## AstraZeneca Plc ## ## ## ## ## ## ## ## AbbVie Inc ## ## ## ## ## ## ## ## Pf

  • Oncology
  • Targeted Therapy
  • United States
  • World
  • Product Initiative

The primary outcome measure of the trial was to determine the safety and tolerability of repeated doses of NOX-A## alone and in combination with filgrastim in healthy subjects.

  • Hospital
  • Pharmaceutical
  • Targeted Therapy
  • Therapy
  • Juventas Therapeutics, Inc.

## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## Japan ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Canada Source: GlobalData' s Phar

  • General Medicine And Specialty Medicine
  • Targeted Therapy
  • Therapy
  • World
  • Product Initiative

The prominent features of this report are - ##.

  • Clinical Trial
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Novartis AG
  • NORTH AMERICA: BIOSIMILARS MARKET SIZE, BY COUNTRY, 2014-2021 (USD BILLION)
  • BIOSIMILARS MARKET SIZE, BY REGION, 2014-2021 (USD BILLION)

One of the important milestones realized on this front was the FDA approval for Sandoz' s (Germany) filgrastim biosimilar-Zarxio (filgrastim-sndz)-for all five indications of the originator product-Neupogen-in 2015.

  • Targeted Therapy
  • North America
  • United States
  • World
  • Market Size

The prominent features of this report are - ##.

  • Cancer
  • Targeted Therapy
  • Therapy
  • World
  • Eli Lilly & Co.

Gland Surgery; ##(##): ##-## Zhang P, et al. (2016).

  • Targeted Therapy
  • World
  • Market Size
  • AstraZeneca PLC
  • Roche Group
  • Clinical Trial profile. 24 Trial Title

The prominent features of this report are - ##.

  • Cancer
  • Clinical Trial
  • Targeted Therapy
  • United States
  • World
  • Clinical Trial profile. 566 Trial Title
  • Clinical Trial profile. 779 Trial Title

Ovarian Cancer Global Clinical Trials Review, H1, 2018 Summary GlobalData’s clinical trial report, “Ovarian Cancer Global Clinical Trials Review, H1, 2018" provides an overview of Ovarian Cancer clinical trials scenario.This report provides top line data relating to the clinical trials on Ovarian...

  • Cancer
  • Clinical Trial
  • Ovarian Cancer
  • Targeted Therapy
  • World

## ## ## ## ## ## ## ## Italy ## ## ## ## ## ## ## ## Germany ## ## ## ## ## ## ## ## United Kingdom ## ## ## ## ## ## ## ## France ## ## ## ## ## ## ## ## Canada ## ## ## ## ## ## ## ## Source: GlobalData' s Pharma Intellige

  • Blood Disease
  • Leukemia
  • Targeted Therapy
  • Therapy
  • Novartis AG